Cannaflex Opens European Export Route

RABAT – Moroccan operator Cannaflex has secured EU-GMP compliance verification for the commercial export of medical Cannabis starting materials to Switzerland and broader European markets, marking an operational milestone for the Kingdom’s legal framework.

Working in collaboration with Swiss-based Pharmaserv AG, the documented supply pathway links GACP-certified cultivation in Morocco’s historic Rif region directly with analytical batch release procedures and dispensing infrastructure through licensed Swiss pharmacies.

The export clearance builds upon Morocco’s regulatory framework overseen by the National Agency for the Regulation of Cannabis Activities (ANRAC). By converting traditional landrace genetics, specifically the local Beldia strain, into standardized active pharmaceutical ingredients (APIs), the operator satisfies stringent European Quality Manager and Qualified Person (QP) release criteria.

Historically, European importers relied on supply corridors originating in Canada, Portugal, and the Netherlands. The establishment of a certified North African supply chain introduces a cost-effective, high-volume production source capable of meeting strict European Pharmacopoeia standards.

The transition follows previous pilot shipments to international markets including Germany, Australia, and South Africa. By finalizing a repeatable EU-GMP release mechanism with Swiss partners, the company shifts from exploratory trial batches to sustained commercial distribution across European pharmacy networks.

Achieving compliance requires rigorous analytical alignment, including heavy metal screening, pesticide clearance, stable cannabinoid profiles, and full supply chain traceability from cooperative farms to final extraction facilities.

The formal integration of Moroccan medical Cannabis into Swiss and European pharmaceutical channels represents a structural shift in global supply logistics. For years, European medical markets faced high production costs and supply chain bottlenecks, relying heavily on indoor cultivation hubs in Western Europe and North America. The emergence of a compliant, sun-grown supply corridor in North Africa offers European distributors a sustainable, scalable alternative capable of lowering wholesale input costs for active pharmaceutical ingredients.

Equally important is the validation of indigenous genetics within a standardized pharmaceutical framework. Rather than replacing native crops with imported Western hybrids, the successful export of refined Beldia extracts demonstrates that traditional landraces can meet rigorous EU-GMP quality controls when paired with modern post-harvest processing and laboratory oversight. This sets a precedent for other nations attempting to transition traditional agricultural regions into regulated, export-oriented medical industries.

Photo courtesy: cannaflex.ma